Breast Cancer With Over-expression of erbB2-BRAINSTORM
Status:
Completed
Trial end date:
2011-06-03
Target enrollment:
Participant gender:
Summary
This retrospective cohort study aims to improve our understanding of the current paradigm for
treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We
aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases
diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the
treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives
are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to
investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time
interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence
of brain metastasis as the first site of disease progression.